Non-psychoactive cannabinoids (including CBD) have been studied extensively for almost three decades in animal models, see PubMed for thousands of independent studies, just a few are cited here. 

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects

British Journal of Pharmacology, Volume 163, Issue 7 – 19 Articles on Cannabinoids

Antitumorigenic Effects of Cannabinoids beyond Apoptosis

Beta-caryophyllene is a dietary cannabinoid

Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

Safety and side effects of cannabidiol, a Cannabis sativa constituent.

Effects of cannabidiol in animal models predictive of antipsychotic activity.

A Study of Infraspecific Flavonoid Variation of Cannabis Sativa L.

Phytocannabinoids beyond the Cannabis plant – do they exist?

A Chemotaxonomic Analysis of Cannabinoid Variation in Cannabis (Cannabaceae)

Cannabinoid and Terprnoid Reference Guide

Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts?

The draft genome and transcriptome of Cannabis sativa

Pharmacokinetics of cannabidiol in dogs

Cannabinoids reduce the progression of Alzheimer’s disease in animals

Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis.

Cloning and pharmacological characterization of the dog cannabinoid CB₂ receptor.

CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs.

Pharmacokinetics of the dimethylheptyl homolog of cannabidiol in dogs.

Comparative metabolism of cannabidiol in dog, rat and man.
CB₂: therapeutic target-in-waiting.

Phytocannabinoids and endocannabinoids.

Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents

Delayed disease progression in ALS mice by treatment with a cannabinoid

Cardiovascular Pharmacology Time-dependent vascular actions of cannabidiol in the rat aorta

Industrial hemp decreases intestinal motility stronger than indian hemp in mice.

Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.

Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation.

Cannabis and Amyotrophic Lateral Sclerosis: Hypothetical and Practical Applications, and a Call for Clinical Trials

Cannabidiol and D9-THC are neuroprotective antioxidants

Neuroprotective antioxidants from marijuana

Cannabis Relieves Lou Gehrigs Symptoms

Prevention of Alzheimer’s Disease Pathology by Cannabinoids

Marijuana Slows Alzheimer’s Decline

Cannabinoids and the skeleton: from marijuana to reversal of bone loss.

Cannabinoids and bone: friend or foe?

Role of cannabinoids in the regulation of bone remodeling.

Cannabis in Palliative Medicine: Improving Care and Reducing Opioid-Related Morbidity

Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro.

Endocannabinoids are expressed in bone marrow stromal niches and play a role in interactions of hematopoietic stem and progenitor cells with the bone marrow microenvironment.

The emerging role of the endocannabinoid system in cardiovascular disease.

The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Marijuana Extract Helps Arthritis Pain

Rheumatoid arthritis, Cannabis based medicine eases pain and suppresses disease

Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

The endocannabinoid system and energy metabolism.

The emerging role of the endocannabinoid system in endocrine regulation and energy balance.

Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.

The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity

Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss.

Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity.

Cannabinoids in eating disorders and obesity.

[Cannabinoid system and feeding regulation]. [Spanish]

Endogenous cannabinoid system as a modulator of food intake.

The endocannabinoid system and the treatment of obesity.

Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood.

[Endocannabinoid system and energy metabolism: physiology and pathophysiology]. [Italian]

Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases.

Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.

The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?

The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation.

Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications.

A Comparison of the Ocular and Central Effects of Δ9-Tetrahydrocannabinol and Cannabigerol.

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.

The endocannabinoid system as a target for the treatment of motor dysfunction.

The endocannabinoid system in Huntington’s disease.

Prospects for cannabinoid therapies in basal ganglia disorders.

Cannabinoids and Parkinson’s disease.

Cannabinoids and neuroprotection in motor-related disorders.

Stimulation of CB1 Cannabinoid and NMDA Receptors Increases Neuroprotective Effect against Diazinon-Induced Neurotoxicity

Role of CB2 receptors in neuroprotective effects of cannabinoids.

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease.

Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method

Effects of a topically applied 2% delta-9-tetrahydrocannabinol ophthalmic solution on intraocular pressure and aqueous humor flow rate in clinically normal dogs.

Cannabinoids inhibit nitric oxide production in bone marrow derived feline macrophages.

Antibacterial Cannabinoids from Cannabis sativa: A Structure−Activity Study

[Cannabis and cannabinoids as drugs] Article in Norwegian.

Chemistry, metabolism, and toxicology of cannabis: clinical implications.

Pharmacological actions of cannabinoids.

Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective.

Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies

The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease

Marijuana in the management of amyotrophic lateral sclerosis

Cannabidiol-caused depression of spinal motoneuron responses in cats.

CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.

Evidence for novel cannabinoid receptors.

Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders.

Therapeutic potential of cannabinoids in CNS disease.

The neurobiology and evolution of cannabinoid signalling.

Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus.

Regulation of nausea and vomiting by cannabinoids.

Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain.

The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview.

The cannabinoid system and pain: towards new drugs?]. [French]

Vascular targets for cannabinoids: animal and human studies

Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol.

Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannabinol.

Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy.

[The pharmacology of cannabinoid derivatives: are there applications to treatment of pain?]. [French]

The cannabinoids as potential antiepileptics.

Cannabinoids: Defending the Epileptic Brain

Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures.

Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions?

Marijuana treatments for autoimmune disorders

Cannabidivarin is anticonvulsant in mouse and rat.

Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.

Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.

Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation

Cannabinoids as potential new therapy for the treatment of gliomas

A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma

Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas

Cannabis: discrimination of “internal bliss”?

Cannabis: pharmacology and toxicology in animals and humans.

The Endocannabinoid System as an Emerging Target of Pharmacotherapy

The pharmacology of cannabinoid receptors and their ligands: an overview.

Cannabinoids, immune system and cytokine network.

Targeting cannabinoid agonists for inflammatory and neuropathic pain.

Antineoplastic activity of cannabinoids.